Allspring Global Investments Holdings LLC Purchases 38,552 Shares of Glaukos Corporation $GKOS

Allspring Global Investments Holdings LLC raised its holdings in shares of Glaukos Corporation (NYSE:GKOS) by 10.9% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 393,831 shares of the medical instruments supplier’s stock after buying an additional 38,552 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Glaukos were worth $44,361,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. First Horizon Corp raised its holdings in shares of Glaukos by 1,715.4% in the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 223 shares during the period. Los Angeles Capital Management LLC purchased a new position in Glaukos during the 4th quarter valued at $28,000. Larson Financial Group LLC boosted its holdings in Glaukos by 62.0% during the 4th quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after acquiring an additional 132 shares during the period. Farther Finance Advisors LLC grew its position in Glaukos by 111.4% in the 4th quarter. Farther Finance Advisors LLC now owns 408 shares of the medical instruments supplier’s stock valued at $46,000 after acquiring an additional 215 shares during the last quarter. Finally, Salomon & Ludwin LLC grew its position in Glaukos by 111.2% in the 4th quarter. Salomon & Ludwin LLC now owns 454 shares of the medical instruments supplier’s stock valued at $51,000 after acquiring an additional 239 shares during the last quarter. Institutional investors own 99.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the company. Piper Sandler reiterated an “overweight” rating and set a $165.00 target price on shares of Glaukos in a research report on Wednesday, July 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Glaukos in a research note on Tuesday, April 21st. Needham & Company LLC boosted their price objective on shares of Glaukos from $136.00 to $150.00 and gave the company a “buy” rating in a research report on Wednesday, June 17th. Wells Fargo & Company upped their target price on shares of Glaukos from $135.00 to $138.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Finally, Truist Financial raised their target price on shares of Glaukos from $160.00 to $180.00 and gave the stock a “buy” rating in a research report on Thursday. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Glaukos has an average rating of “Moderate Buy” and a consensus target price of $154.85.

Glaukos Trading Up 1.0%

Shares of NYSE GKOS opened at $156.97 on Friday. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $161.53. The business has a fifty day moving average price of $134.39 and a 200 day moving average price of $122.04. The stock has a market capitalization of $9.22 billion, a P/E ratio of -47.86 and a beta of 0.75. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.43 and a quick ratio of 4.73.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, April 29th. The medical instruments supplier reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. The business had revenue of $150.57 million during the quarter, compared to the consensus estimate of $137.00 million. Glaukos had a negative net margin of 34.34% and a negative return on equity of 6.92%. The firm’s revenue was up 41.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.22) earnings per share. Equities research analysts expect that Glaukos Corporation will post -0.57 EPS for the current fiscal year.

Insiders Place Their Bets

In other Glaukos news, Director Gilbert H. Kliman sold 5,000 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $140.76, for a total value of $703,800.00. Following the completion of the sale, the director directly owned 35,528 shares in the company, valued at approximately $5,000,921.28. This trade represents a 12.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Leana Wen sold 1,700 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total transaction of $243,695.00. Following the transaction, the director owned 19,739 shares in the company, valued at $2,829,585.65. The trade was a 7.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 61,273 shares of company stock valued at $8,882,003. Company insiders own 5.90% of the company’s stock.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.